Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS

Blood (2008) 112 (8): 3434–3443.

https://doi.org/10.1182/blood-2008-02-139824

Published: 2008

Includes: Supplemental data

Journal Articles

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors

Tony A. Navas, Mani Mohindru, Myka Estes, Jing Ying Ma, Lubomir Sokol, Perry Pahanish, Simrit Parmar, Edwin Haghnazari, Li Zhou, Robert Collins, Irene Kerr, Aaron N. Nguyen, Yin Xu, Leonidas C. Platanias, Alan A. List, Linda S. Higgins, Amit Verma

Blood (2006) 108 (13): 4170–4177.

https://doi.org/10.1182/blood-2006-05-023093

Published: 2006

Journal Articles

SD-208, a Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor, Can Stimulate Hematopoiesis in Myelodysplastic Syndrome Progenitors.

Amit Verma, Tony A. Navas, Jing Ying, Ma, Aaron N. Nguyen, Perry Pahanish, Mahesh Seetharam, Irene Kerr, Robert Collins, Mimi Kim, Mani Mohindru, Linda S. Higgins

Blood (2005) 106 (11): 3448.

https://doi.org/10.1182/blood.V106.11.3448.3448

Published: 2005

Journal Articles

SCIO-469, a Potent and Selective Inhibitor of the p38a MAPK, Inhibits TNFa-Induced Adhesion of Multiple Myeloma Cells to Bone Marrow Stromal Cells Via Downregulation of Chemokines CXCL10/IP-10 and CCL8.

Aaron N. Nguyen, PhD, Gilbert O’ Young, Diana Quon, Debby Damm, Ann M. Kapoun, PhD, Linda S. Higgins, PhD, Tony A. Navas, PhD

Blood (2005) 106 (11): 1569.

https://doi.org/10.1182/blood.V106.11.1569.1569

Published: 2005

Journal Articles

TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

Toshiaki Hayashi, MD, PhD, Teru Hideshima, MD, PhD, Klaus Podar, MD, PhD, Paul Richardson, MD, Olivier Munoz, MD, Makoto Hamasaki, MD, PhD, Kenji Ishitsuka, MD, PhD, Hiroshi Yasui, MD, PhD, Alison Murphy, PhD, Glenn McEnroe, PhD, Sarvajit Chakravarty, PhD, Sundeep Dugar, PhD, Linda S. Higgins, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2355.

https://doi.org/10.1182/blood.V104.11.2355.2355

Published: 2004

Journal Articles

p38 alpha MAP Kinase Inhibitor Inhibits Human Myeloma Cell Growth in Vivo.

Mamatha Reddy, M.S, Jing Y. Ma, M.D, Irene Kerr, A.A, Nirupama Henjarappa, B.S, Tony Navas, Ph.D, Jit Chakravarty, Ph.D, Sundeep Dugar, Ph.D, Linda S. Higgins, Ph.D, Andrew A. Protter, Ph.D, Satyanarayana Medicherla, Ph.D

Blood (2004) 104 (11): 4936.

https://doi.org/10.1182/blood.V104.11.4936.4936

Published: 2004

Journal Articles

Inhibition of p38 MAPK by SCIO-469 Suppresses TNF Generation and Promotes CD34+ Cell Survival in an In Vitro MDS Cell Culture Model.

Tony A. Navas, Ph.D., Aaron N. Nguyen, Ph.D., Jing Y. Ma, M.D., Elizabeth G. Stebbins, Ph.D., Edwin Haghnazari, Ph.D., Ruth Heaton, Alan F. List, M.D., Linda S. Higgins, Ph.D.

Blood (2004) 104 (11): 3424.

https://doi.org/10.1182/blood.V104.11.3424.3424

Published: 2004

Journal Articles

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Teru Hideshima, MD, PhD, Klaus Podar, MD, PhD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Makoto Hamasaki, MD, PhD, Noopur Raje, MD, Hiromasa Hideshima, George Schreiner, MD, PhD, Aaron Nguyen, PhD, Tony Navas, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Linda S. Higgins, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3348.

https://doi.org/10.1182/blood.V104.11.3348.3348

Published: 2004

Journal Articles

SCIO-469, a Potent and Selective Inhibitor of p38a MAPK, Normalizes the Bone Marrow Microenvironment and Inhibits Multiple Myeloma Cell Proliferation in In Vitro and In Vivo Models.

Aaron N. Nguyen, PhD, Mamatha Reddy, MS, Margaret Henson, MS, Elizabeth G. Stebbins, PhD, Gilbert O’Young, BS, Jing Y. Ma, MD, Edwin Haghnazari, PhD, Ann M. Kapoun, PhD, Satya Medicherla, PhD, Andy Protter, PhD, Tony A. Navas, PhD, Linda S. Higgins, PhD

Blood (2004) 104 (11): 1501.

https://doi.org/10.1182/blood.V104.11.1501.1501

Published: 2004

NARROW

Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors

SD-208, a Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor, Can Stimulate Hematopoiesis in Myelodysplastic Syndrome Progenitors.

SCIO-469, a Potent and Selective Inhibitor of the p38a MAPK, Inhibits TNFa-Induced Adhesion of Multiple Myeloma Cells to Bone Marrow Stromal Cells Via Downregulation of Chemokines CXCL10/IP-10 and CCL8.

TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

p38 alpha MAP Kinase Inhibitor Inhibits Human Myeloma Cell Growth in Vivo.

Inhibition of p38 MAPK by SCIO-469 Suppresses TNF Generation and Promotes CD34+ Cell Survival in an In Vitro MDS Cell Culture Model.

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

SCIO-469, a Potent and Selective Inhibitor of p38a MAPK, Normalizes the Bone Marrow Microenvironment and Inhibits Multiple Myeloma Cell Proliferation in In Vitro and In Vivo Models.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only